Download securities and exchange commission - corporate

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 10, 2007
Neuralstem, Inc.
(Exact name of registrant as specified in Charter)
Delaware
000-1357459
52-2007292
(State or other jurisdiction of
incorporation or organization)
(Commission File No.)
(IRS Employee Identification No.)
9700 Great Seneca Highway, Rockville, Maryland 20850
(Address of Principal Executive Offices)
(301) 366-4841
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Appointment of Certain Officers
Effective April 1, 2007, Neuralstem, Inc. (“Company”) appointed John Conron, age 56, as Chief Financial Officer. Mr. Conron, a
Certified Public Accountant, joins the Company after 30 plus years in the field of corporate finance. Since 2003, Mr. Conron has been
consulting early stage companies by providing critical outsource CFO functions such as implementation of accounting systems,
creation and monitoring of internal controls, Sarbanes Oxley compliance, audit preparation, financial modeling and strategic planning.
Prior to his work as a consultant, Mr. Conron worked for Cyberstar, Inc., a wholly owned subsidiary of Loral Space &
Communications, Inc., where he held the position of CFO from 2000 to 2003. Mr. Conron joined Cyberstar from Transworld
Telecommunications, Inc., a Qualcom spin-off which offered telecommunication services in Russia, where he served as CFO.
Mr. Conron also served as CFO and on the board of directors of Mercury Communications in London. Mercury is a European
subsidiary of Cable & Wireless.
Mr. Conron has not entered into any related person transactions with the Company.
Item 8.01
Other Events
On April 10, 2007, Neuralstem, Inc. issued a press release announcing that appointment of John Conron as Chief Financial Officer.
A copy of that press release is attached to this report as Exhibit 99.1.
Item 9.01
Financial Statement and Exhibits.
Exhibit
Number
Description
99.1
Press Release Dated April 10, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form
8-K to be signed on its behalf by the undersigned hereunto duly authorized.
NEURALSTEM, INC.
By:
/s/ I. Richard Garr
I. Richard Garr
Chief Executive Officer
Dated: April 10, 2007
Exhibit 99.1
John Conron Joins Neuralstem as Chief Financial Officer
ROCKVILLE, Md., April 10 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (OTC Bulletin Board: NRLS), a stem cell company focusing
on treatments for central nervous system diseases and conditions, announced the appointment of John Conron to the position of Chief
Financial Officer, a new position.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )
"John Conron is a veteran finance executive who brings a wealth of public company experience to Neuralstem, both here and abroad.
This will prove particularly valuable as the company is preparing to move onto a National exchange and begins to look at expansion
options around the world," said Richard Garr, Neuralstem CEO.
Conron, age 56, joins Neuralstem from Loral Space & Communications Cyberstar, Inc. a global provider of high-quality data, video,
content, and Internet services, where he held the position of CFO, and consolidated its global administrative and finance functions.
Mr. Conron also was CFO at Transworld Telecommunications, Inc., a Qualcom spin-off, which offered telecommunications services
in Russia, where he developed financial and operations strategy response to changes in the countries economic environment.
Mr. Conron spent twenty years at Cable & Wireless, one of the world's leading international communications companies. During his
tenure there, Mr. Conron rose to the position of CFO and member of the Board of Directors at Mercury Communications, in London,
Cable & Wireless's European operations with $2.7 billion in gross revenues.
About Neuralstem
Neuralstem's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and
spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant
human neurons and glia. The Company expects that its first Investigational New Drug (IND) application will be for the treatment of
Ischemic Spastic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which
there is no effective treatment. The Company hopes to submit its initial IND application to the FDA and begin its first human trial
during calendar year 2007.
Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic
Spastic Paraplegia, Traumatic Spinal Cord Injury, ALS, and Parkinson's Disease. The company's cells recently extended the life of
rats with ALS (Lou Gehrig's disease) in a paper published in the journal TRANSPLANTATION, and were deemed viable for
continued work in neurodegenerative spinal conditions. The company has also developed immortalized human neural stem cells for
in-vitro use in drug development for the academic and pharmaceutical markets. For further information, please visit
www.neuralstem.com.
This press release contains forward-looking statements. Neuralstem wishes to caution the readers of this press release that actual
results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, US
FDA responses, and responses from other jurisdictions, to various regulatory submissions; SEC responses to various registration
submissions; changes in corporate strategy; the need to raise additional capital; the success or failure of other private and public
organizations and/or academic and corporate institutions engaged in stem cell research and development, and the market for stem cell
research in general. For further information, please review the company's SB-2 filing with the Securities and Exchange Commission,
and its 10-Q for the quarter ending March 31, 2007.
SOURCE Neuralstem, Inc.
-0-
04/10/2007
/CONTACT: Richard Garr, President of Neuralstem, Inc., +1-301-366-4960;
or Media, Deanne Eagle of Planet Communications, +1-917-837-5866; or
Investors, Ira Weingarten, +1-805-897-1880 or Steve Chizzik, +1-908-688-9111,
both of Equity Communications/
/Photo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO /
/Web site: www.neuralstem.com/
(NRLS)
CO: Neuralstem, Inc.
ST: Maryland
IN: MTC HEA OTC
SU: PER
AZ-AA
-- NETU051a -2670 04/10/2007 08:00 EDT http://www.prnewswire.com